MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by Up-regulating the topoisomerase i activity

Journal of Thoracic Oncology

Volumn 7, Issue 9, 2012, Pages 1337-1344

  Sakai, Asao ^a   Kasahara, Kazuo ^a   Ohmori, Tohru ^b   Kimura, Hideharu ^c   Sone, Takashi ^a   Fujimura, Masaki ^a   Nakao, Shinji ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b SHOWA UNIVERSITY   (Japan)

^c KINKI UNIVERSITY   (Japan)

Author keywords

Epidermal growth factor receptor tyrosine kinase inhibitors resistance; MET; Topoisomerase I

Indexed keywords

DNA TOPOISOMERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; FIRTECAN; GEFITINIB; MESSENGER RNA; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA; TETRAZOLIUM; VINCRISTINE;

ARTICLE; CANCER CELL CULTURE; CELL STIMULATION; CELL VIABILITY; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84865700443     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31825cca4c     Document Type: Article

References (45)

1. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37 Suppl 4:S9-S15. (Pubitemid 32938124)
2. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-6565. (Pubitemid 32197693)
3. Veale D, Ashcroft T, Marsh C, Gibson GJ, Harris AL. Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer 1987;55:513-516. (Pubitemid 17098858)
4. Veale D, Kerr N, Gibson GJ, Kelly PJ, Harris AL. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 1993;68:162-165. (Pubitemid 23178571)
5. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139. (Pubitemid 38637993)
6. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500. (Pubitemid 38720929)
7. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-13311. (Pubitemid 39209661)
8. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007;98:1817-1824. (Pubitemid 350002184)
9. Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006;24:3340-3346. (Pubitemid 46638887)
10. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-2449.
11. Sunaga N, Tomizawa Y, Yanagitani N, et al. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer 2007;56:383-389. (Pubitemid 46679091)
12. Asahina H, Yamazaki K, Kinoshita I, et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006;95:998-1004. (Pubitemid 44606825)
13. Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006;12:6494-6501. (Pubitemid 44799723)
14. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043. (Pubitemid 46799492)
15. Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006;12:5764-5769. (Pubitemid 44629607)
16. Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005;102:11011-11016. (Pubitemid 41105984)
17. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-792. (Pubitemid 40271173)
18. McDermott U, Pusapati RV, Christensen JG, Gray NS, Settleman J. Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res 2010;70:1625-1634.
19. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
20. Farhat FS. A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer. Med Oncol 2007;24:137-146. (Pubitemid 350139221)
21. Krauze MT, Noble CO, Kawaguchi T, et al. Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro-oncology 2007;9:393-403.
22. Ohmori T, Podack ER, Nishio K, et al. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem Biophys Res Commun 1993;192:30-36. (Pubitemid 23205264)
23. Rivory LP Robert J. Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives. Pharmacol Ther 1995;68:269-296. (Pubitemid 26094035)
24. Dean FB, Bullock P, Murakami Y, Wobbe CR, Weissbach L, Hurwitz J. Simian virus 40 (SV40) DNA replication: SV40 large T antigen unwinds DNA containing the SV40 origin of replication. Proc Natl Acad Sci USA 1987;84:16-20. (Pubitemid 17013569)
25. Niwa K, Misao R, Hanabayashi T, et al. Semi-quantitative analysis of DNA topoisomerase-I mRNA level using reverse transcription-polymerase chain reaction in cancer cell lines: its relation to cytotoxicity against camptothecin derivative. Jpn J Cancer Res 1994;85:869-874. (Pubitemid 24262310)
26. Lynch BJ, Komaromy-Hiller G, Bronstein IB, Holden JA. Expression of DNA topoisomerase I, DNA topoisomerase II-alpha, and p53 in metastatic malignant melanoma. Hum Pathol 1998;29:1240-1245. (Pubitemid 28525523)
27. Potmesil M. Camptothecins: from bench research to hospital wards. Cancer Res 1994;54:1431-1439. (Pubitemid 24106402)
28. Coleman LW, Rohr LR, Bronstein IB, Holden JA. Human DNA topoisomerase I: An anticancer drug target present in human sarcomas. Hum Pathol 2002;33:599-607. (Pubitemid 34827540)
29. Ando K, Ohmori T, Inoue F, et al. Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib. Clin Cancer Res 2005;11(24 Pt 1):8872-8879. (Pubitemid 43005940)
30. Trask DK, Muller MT. Biochemical characterization of topoisomerase I purified from avian erythrocytes. Nucleic Acids Res 1983;11:2779-2800.
31. Trask DK, DiDonato JA, Muller MT. Rapid detection and isolation of covalent DNA/protein complexes: application to topoisomerase I and II. EMBO J 1984;3:671-676.
32. Cikos S, Bukovská A, Koppel J. Relative quantification of mRNA: comparison of methods currently used for real-time PCR data analysis. BMC Mol Biol 2007;8:113.
33. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-408. (Pubitemid 34164012)
34. Okabe T, Okamoto I, Tsukioka S, et al. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification. Clin Cancer Res 2009;15:907-913.
35. Horiike A, Kudo K, Miyauchi E, et al. Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer. Br J Cancer 2011;105:1131-1136.
36. Shimoyama T, Koizumi F, Fukumoto H, et al. Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR. Lung Cancer 2006;53:13-21. (Pubitemid 43831356)
37. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802-804. (Pubitemid 21926175)
38. Naldini L, Vigna E, Narsimhan RP, et al. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene 1991;6:501-504. (Pubitemid 21924112)
39. Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006;6:637-645. (Pubitemid 44140861)
40. Yano S, Wang W, Li Q, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008;68:9479-9487.
41. Guo A, Villén J, Kornhauser J, et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 2008;105:692-697. (Pubitemid 351171770)
42. Nakamura Y, Niki T, Goto A, et al. c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. Cancer Sci 2007;98:1006-1013. (Pubitemid 46865384)
43. Masuya D, Huang C, Liu D, et al. The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients. Br J Cancer 2004;90:1555-1562. (Pubitemid 38648238)
44. Ma PC, Tretiakova MS, MacKinnon AC, et al. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 2008;47:1025-1037.
45. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-925. (Pubitemid 37493640)